section name header

Pronunciation ⬇

glye-ME-pye-ride

Classifications ⬆ ⬇

Therapeutic Classification: antidiabetics

Pharmacologic Classification: sulfonylureas

Indications ⬆ ⬇

BEERS REMS, High Alert

Action ⬆ ⬇

  • Lowers blood sugar by stimulating the release of insulin from the pancreas and increasing the sensitivity to insulin at receptor sites.
  • May also decrease hepatic glucose production.
  • May be used concurrently with metformin when the combination of diet, exercise, and either drug alone fails to produce glycemic control.
Therapeutic effects:
  • Lowering of blood sugar in diabetic patients.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 99.5%.

Metabolism/Excretion: Mostly metabolized by the liver; one metabolite has hypoglycemic activity.

Half-Life: 5–9.2 hr.

Time/Action Profile ⬆ ⬇

(hypoglycemic activity)

ROUTEONSETPEAKDURATION
POunknown2–3 hr24 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: photosensitivity, rash

Endo: hypoglycemia

F and E: hyponatremia

GI: constipation, cramps , diarrhea, dyspepsia, hepatitis, nausea, vomiting

Hemat: hemolytic anemia, thrombocytopenia

Metab: ↑appetite

Neuro: dizziness, drowsiness, headache, weakness

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Toxicity and Overdose:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Amaryl

Code ⬆

NDC Code